A Case of Multidrug-Resistant Salmonella enterica Serovar Typhi Treated with a Bench to Bedside Approach.
10.3349/ymj.2009.50.1.147
- Author:
Hee Jung YOON
1
;
Soung Hoon CHO
;
Seong Han KIM
Author Information
1. Department of Internal Medicine, Eulji University College of Medicine, Daejeon, Korea. yhj822@medimail.co.kr
- Publication Type:Case Report
- Keywords:
Salmonella enterica serovar Typhi;
multi-drug resistance;
treatment
- MeSH:
Adult;
Anti-Bacterial Agents/*administration & dosage;
Aztreonam/*administration & dosage;
Bacteremia/drug therapy/microbiology;
Drug Resistance, Bacterial/genetics;
Drug Resistance, Multiple/genetics;
Drug Therapy, Combination;
Humans;
Male;
Salmonella typhi/*drug effects/genetics;
Thienamycins/*administration & dosage;
Typhoid Fever/*drug therapy
- From:Yonsei Medical Journal
2009;50(1):147-151
- CountryRepublic of Korea
- Language:English
-
Abstract:
We report a relapsed case of a 25 year-old man with multi-drug resistant Salmonella serovar Typhi (MDRST) bacteremia who had recently returned from travel in India. Due to unresponsiveness to ciprofloxacin and ceftriaxone, we examined the strain's resistance to quinolones and extended-spectrum beta-lactamases (ESBLs). The strain had a single gyrA mutation at codon 83 (Ser83Phe), which explains its decreased susceptibility to fluoroquinolone and resistance to nalidixic acid. In the screening tests of ESBLs, TEM-1 was positive, which is beta-lactamase but not ESBL. The patient was finally successfully treated with meropenem and aztreonam. In the presence of clinical unresponsiveness despite favorable sensitivity tests, further laboratory evaluations are needed, which should include studies of genes related to antibiotic resistance and ESBLs. In addition, further prospective trials should be done about the possible inclusion of antibiotics not yet mentioned in the current guidelines. With MDRST on the rise worldwide, the most optimal and effective line of antibiotic defense needs to be devised.
